1. Risks of major bleeding and venous thromboembolism in patients undergoing total hip or total knee arthroplasty using therapeutic dosages of DOACs.
- Author
-
Smeets, Mark J. R., Kristiansen, Eskild Bendix, Nemeth, Banne, Huisman, Menno V., Cannegieter, Suzanne C., and Pedersen, Alma Becic
- Abstract
About 1.5% of patients undergoing total hip (THA) or total knee arthroplasty (TKA) still develop postoperative venous thromboembolism (VTE), indicating that the current thromboprophylaxis strategy is not optimal. To evaluate the feasibility of therapeutic dosages of direct oral anticoagulants (DOACs) as thromboprophylaxis for high VTE risk patients, we determined the risks of major bleeding and VTE in patients who underwent THA/TKA and were treated with DOACs in therapeutic dosages for atrial fibrillation (AF). We conducted a registry-based cohort study from 2010 to 2018 in Denmark and included AF patients on therapeutic DOACs dose who underwent THA/TKA. AF patients were utilized as proxy since they have a life-long indication for therapeutic anticoagulant medication. The 49-days cumulative incidence (with death as competing risk) of major bleeding was assessed. The same was done for VTE at 49- and 90-days. 1,354 THA and TKA procedures were included. The 49-days cumulative incidence of major bleeding was 1.40% (95%Confidence Interval[CI] 0.88–2.14%). Most bleeding events occurred at the surgical site. The cumulative incidence of VTE at 49-days was 0.59% (95%CI 0.28–1.13%) and 0.74% (95%CI 0.38–1.32%) at 90-days. The incidence of major bleeding in THA/TKA patients on DOACs in therapeutic dosages was in line with previously reported incidences among THA/TKA patients on thromboprophylaxis dosages, while the incidence of VTE was relatively low. These data provide a solid basis for the design of randomized controlled trials to establish the safety and efficacy of therapeutic dosages of DOACs to prevent VTE in high-risk patients. Essentials: • Some arthroplasty patients still develop venous thromboembolism (VTE), despite thromboprophylaxis. • We assessed the feasibility of DOACs used in therapeutic dosage as thromboprophylaxis in high-risk THA/TKA patients. • Observed risks of major bleeding and VTE were 1.40% (49-days) and 0.74% (90-days), respectively. • A randomized clinical trial investigating the possible benefit of therapeutic dosages of DOACs as prophylactic strategy in high-risk arthroplasty patients seems a feasible next step. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF